Fotios Plakogiannis
Gründer bei Transdermal Research Pharm Laboratories LLC
Profil
Fotios Plakogiannis was the founder of Aequus Pharmaceuticals, Inc. (founded in 2013) and Transdermal Research Pharm Laboratories LLC (founded in 2013) where he held the titles of Director and President, respectively.
He currently holds Director positions at ChemioCare, Inc., Starton Therapeutics, Inc., and HWEL Holdings Corp.
Dr. Plakogiannis previously held the position of Director-Pharmaceutical Sciences Division at Arnold & Marie Schwartz College of Pharmacy & Health Science.
He was also a Professor at Long Island University from 1967 to 2011.
Dr. Plakogiannis holds a doctorate from the University of Southern California and a graduate degree from The Ohio State University.
Aktive Positionen von Fotios Plakogiannis
| Unternehmen | Position | Beginn |
|---|---|---|
| Transdermal Research Pharm Laboratories LLC | Gründer | 01.01.2013 |
ChemioCare, Inc.
 ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | Direktor/Vorstandsmitglied | - |
Starton Therapeutics, Inc.
 Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Fotios Plakogiannis
| Unternehmen | Position | Ende |
|---|---|---|
| AEQUUS PHARMACEUTICALS INC. | Gründer | 10.07.2018 |
| Long Island University | Corporate Officer/Principal | 01.01.2011 |
| Arnold & Marie Schwartz College of Pharmacy & Health Science | Corporate Officer/Principal | - |
Ausbildung von Fotios Plakogiannis
| University of Southern California | Doctorate Degree |
| The Ohio State University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AEQUUS PHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
ChemioCare, Inc.
ChemioCare, Inc. Pharmaceuticals: MajorHealth Technology ChemioCare, Inc. engages in the development and manufacture of pharmaceutical products. The company was founded in 2017 and is headquartered in New York, NY. | Health Technology |
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Health Technology |
| Transdermal Research Pharm Laboratories LLC |
